AI Article Synopsis
- CXCL13 and its receptor CXCR5 are important in understanding the tumor microenvironment for CNS diffuse large B-cell lymphoma (DLBCL).
- CXCL13 found in cerebrospinal fluid serves as a key diagnostic and prognostic marker for CNS-DLBCL, indicating its potential clinical value.
- The review discusses how the CXCL13-CXCR5 axis affects tumor immunity and inflammation in DLBCL and explores its future in immunotherapy applications for CNS-DLBCL.
Article Abstract
Chemokine ligand 13 (CXCL13) and its chemokine receptor 5 (CXCR5) both play significant roles in the tumor microenvironment (TME). CXCL13 in cerebrospinal fluid (CSF) has recently been found to have significant diagnostic and prognostic value in primary and secondary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL), and the CXCL13-CXCR5 axis has been shown to play an important chemotactic role in the TME of CNS-DLBCL. In this review, we first describe the clinical value of CXCL13 in CSF as a prognostic and diagnostic biomarker for CNS-DLBCL. In addition, this review also discusses the specific mechanisms associated with the CXCL13-CXCR5 axis in tumor immunity of primary diffuse large B cell lymphoma of the central nervous system (PCNS-DLBCL) by reviewing the specific mechanisms of this axis in the immune microenvironment of DLBCL and CNS inflammation, as well as the prospects for the use of CXCL13-CXCR5 axis in immunotherapy in PCNS-DLBCL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00277-023-05560-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!